Vertex Pharmaceuticals (NASDAQ:VRTX) Earns “Buy” Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $550.00 price objective on the pharmaceutical company’s stock. VRTX has been the subject of several other reports. Leerink Partners reiterated a “market perform” rating and […]
HC Wainwright reaffirmed their buy rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $550.00 price objective on the pharmaceutical company’s stock. VRTX has been the subject of several other reports. Leerink Partners reiterated a “market perform” rating and […]
